Primary Peritoneal Cancer Clinical Trials

139 clinical trials for Primary Peritoneal Cancer across international registries, including 35 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) — RECRUITING · PHASE3
• A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. — RECRUITING · PHASE2
• Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer — RECRUITING · PHASE2
• Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer — RECRUITING · PHASE1
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer — RECRUITING · PHASE1
• Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer — RECRUITING · PHASE2
• CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer — RECRUITING · PHASE1
• Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) — RECRUITING · PHASE3
• A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) — RECRUITING · PHASE3
• Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer — RECRUITING
• A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies — RECRUITING · PHASE2
• A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine — RECRUITING · PHASE2
• Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors — RECRUITING · PHASE2
• REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors — RECRUITING · NA
• PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer — RECRUITING · PHASE2
• Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype — RECRUITING
• A PHASE 1B/2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RALUDOTATUG DERUXTECAN WITH OR WITHOUT OTHER ANTICANCER INVESTIGATIONAL AGENTS IN PARTICIPANTS WITH HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER WHO HAVE RELAPSED AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY — RECRUITING · PHASE1
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab — RECRUITING · PHASE1
• Study of AVZO-021 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Beta-only IL-2 ImmunoTherapY Study — RECRUITING · PHASE1
• HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer — RECRUITING · PHASE2
• A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF IMGN151 (ANTI-FR¿ ANTIBODY-DRUG CONJUGATE) IN ADULT PATIENTS WITH RECURRENT ENDOMETRIAL CANCER AND RECURRENT, HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS — RECRUITING · PHASE1
• A PHASE 3 STUDY OF RELACORILANT IN COMBINATION WITH NAB-PACLITAXEL VERSUS NAB-PACLITAXEL MONOTHERAPY IN ADVANCED, PLATINUM-RESISTANT HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN-TUBE CANCER (ROSELLA) — RECRUITING · PHASE3
• RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF MIRVETUXIMAB SORAVTANSINE IN COMBINATION WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE AS MAINTENANCE THERAPY FOR PATIENTS WITH FRA-HIGH RECURRENT PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCERS WHO HAVE NOT PROGRESSED AFTER SECOND-LINE PLATINUM-BASED CHEMOTHERAPY PLUS BEVACIZUMAB (GLORIOSA) — RECRUITING · PHASE3
• MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF CARBOPLATIN PLUS MIRVETUXIMAB SORAVTANSINE FOLLOWED BY MIRVETUXIMAB SORAVTANSINE CONTINUATION IN FOLATE RECEPTOR-ALPHA POSITIVE, RECURRENT PLATINUM-SENSITIVE, HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCERS FOLLOWING 1 PRIOR LINE OF PLATINUM-BASED CHEMOTHERAPY — RECRUITING · PHASE2
• A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY OF NEMVALEUKIN ALFA IN COMBINATION WITH PEMBROLIZUMAB VERSUS INVESTIGATOR¿S CHOICE CHEMOTHERAPY IN PATIENTS WITH PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (ARTISTRY-7) — RECRUITING · PHASE3
• MIRASOL: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF MIRVETUXIMAB SORAVTANSINE VS. INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN ADVANCED HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS WITH HIGH FOLATE RECEPTOR-ALPHA EXPRESSION — RECRUITING · PHASE3
• ATHENA (A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY IN OVARIAN CANCER PATIENTS EVALUATING RUCAPARIB AND NIVOLUMAB AS MAINTENANCE TREATMENT FOLLOWING RESPONSE TO FRONT-LINE PLATINUM-BASED CHEMOTHERAPY) — RECRUITING · PHASE3
• PHASE 1 (SAFETY ASSESSMENT) OF DURVALUMAB (MEDI4736) WITH FOCAL SENSITIZING RADIOTHERAPY IN PLATINUM RESISTANT OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE EPITHELIAL CARCINOMA — RECRUITING · PHASE1
• A PHASE 2 STUDY OF PEMBROLIZUMAB (MK-3475), DPX-SURVIVAC VACCINE AND LOW DOSE OF CYCLOPHOSPHAMIDE COMBINATION IN PATIENTS WITH ADVANCED OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCER — RECRUITING · PHASE2
• A RANDOMIZED PHASE II/III STUDY OF THE COMBINATION OF CEDIRANIB AND OLAPARIB COMPARED TO CEDIRANIB OR OLAPARIB ALONE, OR STANDARD OF CARE CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-RESISTANT OR -REFRACTORY OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (COCOS) — RECRUITING · PHASE2
• A PHASE III STUDY COMPARING SINGLE-AGENT OLAPARIB OR THE COMBINATION OF CEDIRANIB AND OLAPARIB TO STANDARD PLATINUM-BASED CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-SENSITIVE OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER — RECRUITING · PHASE3
• A RANDOMIZED, OPEN LABEL PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MIRVETUXIMAB SORAVTANSINE (IMGN853) VERSUS INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN WOMEN WITH FOLATE RECEPTOR A-POSITIVE ADVANCED EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CANCER OR FALLOPIAN TUBE CANCER — RECRUITING · PHASE3
• Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery — ACTIVE_NOT_RECRUITING · PHASE2
• Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod — TERMINATED · PHASE2
• A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα） — NOT_YET_RECRUITING
• "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer — NOT_YET_RECRUITING · PHASE3
• A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer — COMPLETED · PHASE2
• Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer — NOT_YET_RECRUITING · PHASE2
• Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) — ACTIVE_NOT_RECRUITING · PHASE1
• TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer — NOT_YET_RECRUITING · PHASE2
• Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study — COMPLETED
• Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer — COMPLETED · PHASE1
• Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer — NOT_YET_RECRUITING · PHASE2
• Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer — TERMINATED · PHASE1

Refine this search